Floatz logo

zw251

Hepatocellular Carcinoma

Zymeworks BC Inc.Phase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
nrt6003
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Inno-206
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

zw251 is also rated in:

squamous cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
germ cell tumorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →